Loading clinical trials...

Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test

NCT04958109•Massachusetts General Hospital

View on ClinicalTrials.gov

Summary

The goal of this study is to understand how exogenous kisspeptin affects metabolism by evaluating responses to an oral glucose tolerance test

Detailed Description

Assignment: Each study subject will serve as their own control. The order of the visits will be randomized. Delivery of Interventions: * Prior to the study visit, subjects will undergo a review of their medical history and screening laboratories. * During the inpatient study, the subjects will * Undergo a 16-hour kisspeptin infusion * Undergo an oral glucose tolerance test

Eligibility

Age

18 - 40 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•History:
•over the age of 18,
•normal pubertal development
•stable weight for previous three months,
•normal body mass index (BMI between 18.5-25)
•regular menstrual cycles
•Physical examination:
•systolic BP \< 140 mm Hg, diastolic \< 90 mm Hg
•Laboratory studies: (per Massachusetts General Hospital reference ranges)
•normal hemoglobin
+3 more criteria

Exclusion Criteria

•active illicit drug use,
•history of a medication reaction requiring emergency medical care,
•difficulty with blood draws.
•history of chronic disease, except well controlled thyroid disease,
•recent use of prescription medications which interfere with metabolism or reproduction (recent = within 5 half-lives of the drug). Use of levothyroxine or seasonal allergy medications is acceptable,
•history of diabetes in a first degree relative,
•use of contraceptive pills, patches or vaginal rings within last 4 weeks.
•hyperlipidemia by fasting lipid panel
•positive serum pregnancy test (for all women)

Locations (1)

Massachusetts General Hospital

Boston, Massachusetts, United States

Key Dates

Start Date

October 28, 2021

Primary Completion Date

October 31, 2022

Completion Date

October 31, 2022

Last Updated

March 6, 2026

Enrollment

ACTUAL participants

Conditions

Metabolic Diseases

Interventions

Oral Glucose Tolerance Test

DIAGNOSTIC_TEST

Kisspeptin

DRUG

Placebo

DRUG

The Satiety Control Optimization by Nutritional Enhancement Study

NCT07420023

Metabolic Diseases, Type 2 Diabetes, Cardiovascular Disease

View study

RECRUITINGNA

Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet on Cellular Zinc

NCT05236374

Zinc DeficiencyInflammation+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 6, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test

Inclusion Criteria

Exclusion Criteria

The Satiety Control Optimization by Nutritional Enhancement Study

Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet on Cellular Zinc

Postprandial Glucose Levels, Gut Microbiota and Supplementation With Functional Foods in Adults

The Effect of Processing on Food Reward

The SWITCH Dietary and Behavioural Intervention Study

Relationship Between Metabolic Profiles and Chronic Diseases and Neoplasms